CTSK and cerebrovascular disorder: The development of odanacatib, a cathepsin K inhibitor, was discontinued due to an apparent increase in the risk of cerebrovascular disease observed in the pivotal phase 3 study and an increase in the composite MACE endpoint in the phase 3 extension trial of odanacatib (18).